RET (S904A)

RET · Variant type: point · HGVS: p.S904A

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Nintedanib	100.0%	0.0%	90.23
2	Pralsetinib	100.0%	0.0%	93.43
3	Lenvatinib	100.0%	0.0%	97.74
4	Ponatinib	99.7%	0.3%	78.23
5	Regorafenib	99.7%	0.3%	95.99
6	Alectinib	99.5%	0.5%	95.49
7	Cabozantinib	99.1%	0.9%	92.73
8	Alpelisib	98.7%	1.3%	97.22
9	Tivozanib	98.7%	1.4%	92.42
10	Entrectinib	98.7%	1.4%	93.69
11	Fedratinib	98.6%	1.4%	96.21
12	Tenalisib	98.5%	1.5%	97.98
13	Selpercatinib	98.3%	1.7%	96.72
14	Gilteritinib	97.7%	2.4%	88.97
15	Brigatinib	97.5%	2.5%	82.96
16	Sorafenib	97.2%	2.8%	96.72
17	Sunitinib	95.7%	4.3%	91.73
18	Axitinib	95.1%	4.9%	93.23
19	Vandetanib	94.1%	5.9%	95.74
20	Repotrectinib	91.5%	8.5%	84.21
21	Futibatinib	91.1%	8.9%	98.48
22	Apatinib	90.9%	9.1%	97.73
23	Quizartinib	90.2%	9.8%	99.50
24	Erdafitinib	90.0%	10.0%	95.71
25	Fostamatinib	89.9%	10.1%	96.74

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Nintedanib	100.0%	100.0%	+0.0%
Pralsetinib	100.0%	100.0%	+0.0%
Lenvatinib	100.0%	98.8%	+1.2%
Ponatinib	99.7%	100.0%	-0.3%
Regorafenib	99.7%	98.7%	+1.0%
Alectinib	99.5%	97.8%	+1.7%
Cabozantinib	99.1%	97.5%	+1.5%
Alpelisib	98.7%	99.6%	-0.9%
Tivozanib	98.7%	99.7%	-1.1%
Entrectinib	98.7%	99.6%	-0.9%
Fedratinib	98.6%	99.9%	-1.3%
Tenalisib	98.5%	98.5%	-0.0%
Selpercatinib	98.3%	100.0%	-1.7%
Gilteritinib	97.7%	100.0%	-2.3%
Brigatinib	97.5%	94.9%	+2.6%
Sorafenib	97.2%	94.0%	+3.3%
Sunitinib	95.7%	97.2%	-1.5%
Axitinib	95.1%	—	—
Vandetanib	94.1%	98.6%	-4.5%
Repotrectinib	91.5%	—	—
Futibatinib	91.1%	97.7%	-6.6%
Apatinib	90.9%	—	—
Quizartinib	90.2%	—	—
Erdafitinib	90.0%	94.7%	-4.6%
Fostamatinib	89.9%	—	—

Cancer	Organ	Source
carcinoma_thyroid	Thyroid	ref

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.3ms